Can a Practice Use an AI Scribe Without Patient Audio Leaving Australia?

Detailed Explanation

An AI scribe listens to (or is fed a recording of) a clinical consultation and produces a written note — a summary, a set of clinical documentation entries, sometimes a full transcript — without the clinician having to type it themselves. Adoption in Australian general practice has grown quickly, and with that growth has come specific, recent official guidance on exactly the question a practice manager or GP evaluating one of these tools should be asking: where does the audio actually go, and who processes it?

The short answer is that Australian-only handling may be possible, but it depends on the specific vendor, plan and underlying model. A local storage location does not establish where audio is processed. Confirm the actual configuration and contractual terms before using a scribe with patient data.

What the Official Guidance Actually Says

The Australian Commission on Safety and Quality in Health Care's AI Safety Scenario on ambient scribes says patient data must be stored and processed in Australia unless the patient has explicitly consented to offshore handling. This is the Commission's clinical safety guidance, not a statement that the Privacy Act prohibits every overseas disclosure. APP 8 has its own conditions for cross-border disclosure.

Victoria has gone further for its own public health services: the Victorian Department of Health's sector advisory on ambient AI scribes directs that Victorian public health services must only use AI scribes that store and process data within Australia, alongside requiring documented, revocable patient consent and a privacy impact assessment before rollout. That's a binding direction for Victorian public health services specifically — but it's a useful, concrete benchmark for any Australian practice deciding what standard to hold a vendor to, public or private.

Is the Scribe Itself a Regulated Medical Device?

This is a separate question from data residency, and it's easy to conflate the two. The Therapeutic Goods Administration's published position draws a clear functional line: a digital scribe that only transcribes and translates a clinical conversation into written form, without analysing or interpreting it, is not treated as a medical device. A scribe that goes further — analysing the conversation to generate a diagnosis, a differential diagnosis, or a treatment recommendation the clinician didn't explicitly state — crosses into medical-device territory and must be listed on the Australian Register of Therapeutic Goods before it's supplied in Australia. The TGA has stated it is actively reviewing digital scribes on the market against this test, so this is a live compliance question, not a settled one.

Some professional bodies have taken a broader reading of what counts as "not a medical device" than the TGA's own published test — which is a genuine, unresolved tension worth knowing about rather than assuming there's a single, universally agreed answer. When in doubt, check the specific product's current feature set against the TGA's transcribe-versus-interpret test yourself, rather than relying on either the vendor's or a professional body's characterisation alone.

What to Actually Ask a Vendor

1. "Where, specifically, is audio and transcript data stored and processed — not just where the company is headquartered?" A vendor being an Australian company doesn't guarantee Australian data processing; cloud infrastructure and any underlying AI model calls can run offshore even when the front-end product is locally branded and sold.
2. "Can we configure this to guarantee Australian-only processing, and is that the default or an opt-in setting?" Some platforms offer a regional processing option that isn't switched on by default — confirm the actual setting for your account, not just that the feature theoretically exists somewhere in the product.
3. "Does this tool only transcribe, or does it also analyse and interpret the conversation?" This determines whether the TGA's medical-device threshold is relevant to your specific product and plan.
4. "What does your current patient consent process look like, and can we see the actual wording?" A vendor selling into the Australian healthcare market should have a ready answer here, not a vague assurance.
5. "What happens to the audio recording after the note is generated — is it retained, and for how long?" Retention policy is a separate question from processing location, and both matter.

Things to Consider

• This overlaps with, but doesn't replace, the general question of AI tools and data location. See does it matter which country an AI tool stores your data in for the general APP 8 framework this page applies specifically to clinical audio and health information, which the Privacy Act treats as a sensitive category with stricter handling expectations than most other personal data.
• The regulatory picture here is moving quickly and is under active review. The TGA has an open stakeholder consultation specifically reviewing digital scribes supplied in Australia, and Victoria's sector advisory reflects one state health system's binding position rather than a single settled national rule for every practice type. Re-check current guidance periodically rather than treating this page as a permanent snapshot.
• Reducing what an external AI model sees is a related but different technique from choosing a locally hosted vendor. A practice weighing a broader cloud-AI tool for other clinical or administrative tasks may also want to look at how do you strip sensitive data out of a document before it reaches a cloud AI model for the alternative (or complementary) approach of removing identifying details before anything leaves the practice, rather than relying solely on where a vendor says it processes data.
• This sits alongside the practice's broader patient-facing automation, not apart from it. See how do healthcare practices automate patient scheduling and intake for the wider set of automation decisions a practice typically works through, of which an AI scribe is usually one piece.

Common Mistakes

• Assuming an Australian-sounding brand means Australian data processing. Company location, app-store listing region, and where the actual audio processing and any underlying AI model calls happen are three different things — confirm the last one specifically.
• Treating "not a medical device" as a permanent classification rather than a feature-dependent one. A scribe can move from transcription-only into device territory the moment a vendor ships a new clinical-summary or diagnostic-suggestion feature — re-check the classification when a product's feature set changes, not just when you first adopt it.
• Skipping documented patient consent because the recording feels routine. Practices normalise a new workflow quickly; that doesn't remove the obligation to tell patients their consultation is being processed by a third-party AI tool and to give them the option to decline.
• Relying on a vendor's marketing claims about privacy without checking the actual configuration on your specific plan. A "data stays in Australia" claim on a website is not the same as confirming the setting is active on the plan your practice is actually paying for.
• Not revisiting the decision as guidance evolves. With an active TGA consultation and health-department guidance still developing across jurisdictions, a vendor or configuration that was compliant a year ago isn't guaranteed to still be the best-positioned option today.